E-viri
PDF
Recenzirano
Odprti dostop
-
Imber, Brandon S.; Sadelain, Michel; DeSelm, Carl; Batlevi, Connie; Brentjens, Renier J.; Dahi, Parastoo B.; Giralt, Sergio; Park, Jae H.; Sauter, Craig; Scordo, Michael; Shah, Gunjan; Perales, Miguel‐Angel; Palomba, M. Lia; Yahalom, Joachim
British journal of haematology, July 2020, 2020-07-00, 20200701, Letnik: 190, Številka: 1Journal Article
Summary Radiotherapy is potentially an important salvage strategy post‐chimeric antigen receptor T cell therapy (CART), but limited data exist. We reviewed 14 patients treated with salvage radiation post‐CART progression (SRT). Most received SRT for first post‐CART relapse (71%) to sites previously PET‐avid pre‐CART (79%). Median overall survival (OS) post‐SRT was 10 months. Post‐SRT, six localized relapses achieved 100% response (3 = complete, 3 = partial), with improved freedom from subsequent relapse (P = 0·001) and OS (P = 0·004) compared to advanced stage relapses. Three were bridged to allogeneic transplantation; at analysis, all were alive/NED. SRT has diverse utility and can integrate with novel agents or transplantation to attempt durable remissions.
